We describe here a new method for labelling interleukin-2 (IL-2) in high specific activity with Tc-99m for in vivo studies in man. Labelling was performed via a two-step reaction using an N3S bifunctional chelating agent. To optimise the reaction, factors affecting the incorporation of Tc-99m into the N3S ligand were studied. The conjugation of the preformed N3S chelate ligand to IL-2 was then similarly optimised. Various strategies for purifying the Tc-99m-IL-2 were explored including size exclusion, ion exchange, and several modes of reversed-phase chromatography. The radiochemical purity of the purified protein was determined by HPLC, ITLC, TCA precipitation, and SDS-PAGE. The receptor binding capacity of Tc-99m-IL-2 was studied. Biodistribution studies in normal mice were performed with Tc-99m-IL-2 purified using different techniques or labelled after prolonged storage and compared to I-125-IL-2. (C) 1997 Elsevier Science Inc.

The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases / Marco, Chianelli; Signore, Alberto; Alan R., Fritzberg; Stephen J., Mather. - In: NUCLEAR MEDICINE AND BIOLOGY. - ISSN 0969-8051. - STAMPA. - 24:6(1997), pp. 579-586. [10.1016/s0969-8051(97)00021-8]

The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases

SIGNORE, Alberto;
1997

Abstract

We describe here a new method for labelling interleukin-2 (IL-2) in high specific activity with Tc-99m for in vivo studies in man. Labelling was performed via a two-step reaction using an N3S bifunctional chelating agent. To optimise the reaction, factors affecting the incorporation of Tc-99m into the N3S ligand were studied. The conjugation of the preformed N3S chelate ligand to IL-2 was then similarly optimised. Various strategies for purifying the Tc-99m-IL-2 were explored including size exclusion, ion exchange, and several modes of reversed-phase chromatography. The radiochemical purity of the purified protein was determined by HPLC, ITLC, TCA precipitation, and SDS-PAGE. The receptor binding capacity of Tc-99m-IL-2 was studied. Biodistribution studies in normal mice were performed with Tc-99m-IL-2 purified using different techniques or labelled after prolonged storage and compared to I-125-IL-2. (C) 1997 Elsevier Science Inc.
1997
bifunctional chelating agents; immune-mediated diseases; interleukin-2; radiolabelling; technetium-99m
01 Pubblicazione su rivista::01a Articolo in rivista
The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases / Marco, Chianelli; Signore, Alberto; Alan R., Fritzberg; Stephen J., Mather. - In: NUCLEAR MEDICINE AND BIOLOGY. - ISSN 0969-8051. - STAMPA. - 24:6(1997), pp. 579-586. [10.1016/s0969-8051(97)00021-8]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/502208
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 62
social impact